Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer

BACKGROUND: Resistance to androgen receptor signalling inhibitors (ARSIs) represents a major clinical challenge in prostate cancer. We previously demonstrated that the ARSI enzalutamide inhibits only a subset of all AR-regulated genes, and hypothesise that the unaffected gene networks represent pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinneh, Josephine A., Gillis, Joanna L., Mah, Chui Yan, Irani, Swati, Shrestha, Raj K., Ryan, Natalie K., Atsushi, Enomoto, Nassar, Zeyad D., Lynn, David J., Selth, Luke A., Kato, Masashi, Centenera, Margaret M., Butler, Lisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575850/
https://www.ncbi.nlm.nih.gov/pubmed/37673961
http://dx.doi.org/10.1038/s41416-023-02406-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575850/
https://www.ncbi.nlm.nih.gov/pubmed/37673961
http://dx.doi.org/10.1038/s41416-023-02406-8

Ejemplares similares